title: [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
abstract: OBJECTIVE
  The purpose of this study was to reproduce the results obtained by the "BFM Group" in children with NHL and B-ALL treated with BFM 86 and 90 protocols.
  
  
  METHODS
  From April 1987 until January 1997, we have treated a total of 82 children, 22 with non-B NHL, 49 B-NHL and 11 B-ALL. Forty-four of them were treated according to BFM 86 and 38 according to BFM 90 protocols.
  
  
  RESULTS
  Ninety-four percent of the patients achieved complete remission (CR) and 15% of these relapsed, 12% of the cases of B NHL/ALL and 23% of the non-B NHL. The 5 year overall survival (Kaplan Meier) was 81% for the B NHL/ALL it was 83% and for non-B NHL 77%. The event-free survival was 75% for B-NHL, stages I and II it was 80% and stages II and IV 78%, for B-ALL 72% and for non-B NHL 68%. The median follow-up time was 50 months (12-106).
  
  
  CONCLUSIONS
  Treatment of NHL and B-ALL with BFM protocols is an effective therapeutic choice, with reproduction of the results of the "BFM group" being feasible.
authors.affiliation: Sección de Hemato-Oncología Pediátrica, Hospital Materno Infantil 12 de Octubre, Madrid.
authors.forename: J L
authors.initials: JL
authors.lastname: Vivanco Martínez
authors.forename: J
authors.initials: J
authors.lastname: López Pérez
authors.forename: C
authors.initials: C
authors.lastname: Melero Moreno
authors.forename: M J
authors.initials: MJ
authors.lastname: Torres Valdivieso
authors.forename: M E
authors.initials: ME
authors.lastname: Palacios López
authors.forename: T
authors.initials: T
authors.lastname: Contra Gómez
authors.forename: N
authors.initials: N
authors.lastname: Martín Ramos
authors.forename: M
authors.initials: M
authors.lastname: Bernacer Borja
authors.forename: C
authors.initials: C
authors.lastname: Gil López
authors.forename: F
authors.initials: F
authors.lastname: Valverde Moreno
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage